Table 2.
Multivariable Cox Proportional Hazards Models for Isocitrate Dehydrogenase-Wild-Type Newly Diagnosed Glioblastoma Patients From the Ohio Brain Tumor Study (OBTS) and the University of California San Francisco (UCSF), 2007–2017
| OBTS (Training; N = 179) | UCSF (Validation; N = 122) | |||||
|---|---|---|---|---|---|---|
| Factor | HR | 95% CI | P-value | HR | 95% CI | P-value |
| Age | 1.018 | (1.002–1.034) | .026 | 1.025 | (1.005–1.045) | .016 |
| Sex (male vs female) | 1.596 | (1.114–2.285) | .011 | 1.206 | (0.778–1.870) | .402 |
| Surgery (STR vs GTR) | 1.084 | (0.788–1.493) | .620 | 1.011 | (0.634–1.611) | .965 |
| Concurrent radiation/TMZ (yes vs. no) | 0.244 | (0.161–0.369) | <.001 | 0.504 | (0.301–0.845) | .009 |
| KPS (≥70 vs. <70) | 0.351 | (0.237–0.520) | <.001 | 0.308 | (0.163–0.583) | <.001 |
| MGMT methylation (yes vs. no) | 0.579 | (0.395–0.848) | .005 | 0.474 | (0.299–0.764) | .002 |
CI = confidence interval; GTR = gross total resection; HR = hazard ratio; KPS = Karnofsky Performance Status; MGMT = O6-methylguanine-DNA methyltransferase; STR = subtotal resection; TMZ = temozolomide.